Makoto Tahara

Abstract 1107: Prospective observational study to evaluate the efficacy of oxygen saturation endoscopic imaging for radiotherapeutic response in head and neck squamous cell carcinoma 

Cancer Research, 84(6_Supplement) 1107-1107, Mar 22, 2024  

A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan. 

Thyroid : official journal of the American Thyroid Association, Mar 14, 2024  

Current status and future perspective of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck. 

Japanese journal of clinical oncology, Mar 7, 2024  

Long‐term outcomes of patients with oral cavity cancer receiving postoperative radiotherapy after salvage neck dissection for cervical lymph node recurrence 

Head & Neck, Dec 18, 2023  

Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) 

Oral Oncology, 147 106615-106615, Dec, 2023  

Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck 

Frontiers in Oncology, 13, Nov 21, 2023  

Association between baseline blood pressure and the incidence of lenvatinib‐induced hypertension in patients with thyroid cancer 

Cancer Medicine, Oct 30, 2023  

Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study 

Frontiers in Oncology, 13, Oct 11, 2023  

First-Line Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: 5-Year Update of the Japanese Subgroup of KEYNOTE-048(タイトル和訳中) 

日本癌治療学会学術集会抄録集, 61回 FR5-2, Oct, 2023  

アンドロゲン受容体陽性唾液腺癌に対するダロルタミド単剤療法の第II相臨床試験 

日本癌治療学会学術集会抄録集, 61回 O30-2, Oct, 2023  

2228P Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution 

Annals of Oncology, 34 S1147-S1147, Oct, 2023  

A pharmacist-led opioid de-escalation program after completion of chemoradiotherapy in locally advanced head and neck cancer 

Frontiers in Oncology, 13, Sep 15, 2023  

甲状腺がん患者におけるLenvatinib誘発性高血圧の発症実態についての検討 

日本高血圧学会総会プログラム・抄録集, 45回 333-333, Sep, 2023  

Potential efficacy of local therapy for progressive lesions after nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck 

International Journal of Clinical Oncology, Jun 21, 2023  

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin 

Frontiers in Oncology, 13, Jun 15, 2023  

Efficacy and safety of adapalene gel as a reactive treatment for cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck: A historical cohort comparison study. 

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 10781552231171699-10781552231171699, Apr 25, 2023  

Weekly versus 3-weekly cisplatin along with radiotherapy for locoregionally advanced non-nasopharyngeal head and neck cancers: Is the equipoise in literature addressed yet? 

Head & neck, Apr 5, 2023  

Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer 

Frontiers in Oncology, 13, Mar 14, 2023  

甲状腺Lenvatinib療法による高血圧症の発症状況、リスク因子および臨床的転帰についての解析 

日本循環器学会学術集会抄録集, 87回 CO6-2, Mar, 2023  

Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck 

European Journal of Cancer, Feb, 2023